Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Cancer Discovery|2022Cited by 139
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerXuxu Gou, Matthew J. Ellis|Cancer Research|2021Cited by 24
Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0